Objective To study the efficacy of peritoneal perfusion with cisplatin combined with capecitabine for advanced gastric cancer ascites.Methods 70 cases of advanced gastric cancer ascites were randomly divided into the control group and the experimental group,each with 35 cases.The control group injected with cisplatin and intraperitoneal hyperthermic perfusion,the experimental group received peritoneal perfusion with cisplatin combined with capecitabine.After 2 weeks of treatment using RECIST criteria (Solid Tumors evaluation of efficacy) assessment of short-term efficacy;by reducing the B-observation depth range peritoneal fluid areas to assess the effect of treatment of ascites;press card rates to assess the quality of life;used by the US National Cancer Research the toxicity of anticancer drugs and performance grading criteria (NCI-CTC) version 3.0 and toxicity were evaluated.Results Recent objective response rate in the experimental group was 68.6％ (effective number of cases 24 cases),of the control group was 42.8％ (effective number of cases 15 cases),the difference was significant;the control of the disease in the experimental group was 91.4％,the control group was 68.5％,of which malignant ascites effective control of the experimental group was 65.8％,45.6％ in the contral group,the difference was significant.Quality of life score (KPS) in the experimental group before treatment score was 65.1 ± 8.6;87.5 ± 9.0 after treatment;control group before treatment 64.9 ± 8.3,78.9 ± 8.5,the experimental group and control group students quality score improvement rote after treatment respectively were 60.8％ and 45.6％,P ＜ 0.05.There was no significant difference (P ＞ 0.05) in adverse reactions.Conclusion Peritoneal perfusion with cisplatin in combiuation with capecitahine is superior to cisplatin peritoneal peffusion for advanced gastric cancer ascites in efficiency,disease control rate,malignant ascites control efficiency and quality of life scores.%目的 观察卡培他滨化疗结合腹腔热灌注顺铂对晚期胃癌腹腔积液治疗的效果.方法 随机选取晚期胃癌腹腔积液患者70例,将其分为对照组、观察组,各35例.对照组注入顺铂并进行腹腔循环热灌注治疗,实验组腹腔热灌注顺铂治疗基础上结合卡培他滨化疗.治疗2周后,采用tBECIST标准(实体肿瘤疗效评价)评估近期疗效;通过B超观察腹腔液性暗区深度减少范围对腹腔积液治疗效果进行评估;按卡式评分评估生活质量;采用美国国立肿瘤研究所抗肿瘤药物毒性表现和分级标准(NCI-CTC) 3.0版进行不良反应评价.结果 近期客观有效率实验组68.6％ (24/35),对照组42.8％ (15/35),2组差异有统计学意义;疾病控制率实验组91.4％,对照组68.5％;其中癌性腹腔积液控制有效率实验组65.8％,对照组45.6％,2组差畀有统计学意义.生活质量评分(KPS)实验组治疗前评分是(65.1±8.6);治疗后是(87.5±9.0);对照组治疗前(64.9±8.3),治疗后(78.9±8.5).实验组和对照组生活质量评分提高率分别为60.8％和45.6％,P＜0.05.不良反应2组无明显差异(P＞0.05),不具统计学意义.结论 治疗晚期胃癌腹腔积液在有效率、疾病控制率、癌性腹腔积液控制有效率以及生活质量评分方面腹腔热灌注顺铂治疗结合卡培他滨化疗的疗效均优越于单纯接受腹腔热灌注顺铂化疗.
展开▼
